Italfarmaco SpA and Iktos SA have entered into a collaboration to develop next-generation histone deacetylase (HDAC) inhibitors for a variety of non-oncological diseases, including diseases affecting the central nervous system.
Revir Therapeutics Inc. has announced the achievement of a milestone under its ongoing collaboration with Asieris Pharmaceuticals Co. Ltd. to develop treatments for cancers using a novel target.
Alivexis Inc. has entered into a research collaboration agreement with Astellas Pharma Inc. to identify small-molecule compounds for a new drug target selected by Astellas.
Sibylla Biotech SpA and the University of Texas MD Anderson Cancer Center have signed a strategic collaboration agreement to discover and develop novel small molecule folding interfering degraders (FIDs) for the treatment of cancer.
Biosplice Therapeutics Inc. has entered a collaboration with Novo Nordisk A/S to develop first-in-class drug candidates for the treatment of diabetes. Biosplice is developing highly selective and potent dual-specificity tyrosine-regulated kinase (DYRK) inhibitors to stimulate insulin-secreting β-cell proliferation for the treatment of diabetes.
Flagship Pioneering Inc. and Profound Therapeutics Inc., a Flagship-founded company, have announced a collaboration to conduct foundational research to identify potential next-generation first-in-class therapies for the treatment of obesity.
Evotec SE has announced scientific progress within its neuroscience collaboration with Bristol Myers Squibb Co., with a target-based program now advancing into late preclinical development. This milestone triggers a research payment of $20 million to Evotec.
Calidi Biotherapeutics Inc. has announced a collaboration with Siga Technologies Inc. to support the development of Calidi’s systemic and targeted Rtnova (CLD-400) virotherapy platform, which has the potential to provide a universal treatment for all tumor types.
Epiendo Pharmaceuticals ehf and Alveolix AG have achieved significant milestones in their collaboration to advance the treatment of ulcerative colitis.
Aurobac Therapeutics SAS, a biopharmaceutical company founded by Boehringer Ingelheim Pharma GmbH & Co KG, Biomérieux SA and Evotec SE, has announced its strategy to target bacterial infections, antimicrobial resistance and their consequences in acute hospital settings, such as hospital-acquired and ventilator-associated bacterial pneumonia and sepsis.
RSS
